Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsINJECTIONGeneric

NARCAN

NALOXONE HYDROCHLORIDE

Standard Dose
0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: PRIORITY Marketing status: Discontinued
Summary

Approval overview NARCAN is listed in Drugs@FDA under application 016636 (NDA).

Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ADAPT Submission history Latest submission status date: 2002-10-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview NARCAN is listed in Drugs@FDA under application 016636 (NDA). Review priority: PRIORITY Marketing status: Discontinued Active ingredient NALOXONE HYDROCHLORIDE Form and strength INJECTABLE;INJECTION - 0.4MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ADAPT Submission history Latest submission status date: 2002-10-25 00:00:00. Submission type: SUPPL.

Monitoring

  • Marketing status: Discontinued
  • Review priority: PRIORITY

Interaction Notes

  • No interaction notes stored yet.
NARCAN (NALOXONE HYDROCHLORIDE) | Drug Monograph | MedicHelpline